|
|
||||||||
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Journal of Lipid Research, Vol. 45, 536-542, March 2004
Copyright © 2004 by American Society for Biochemistry and Molecular Biology


* Departments of Molecular Sciences, College of Medicine, University of Tennessee Health Science Center, Memphis, TN 38163
Pharmacology, College of Medicine, University of Tennessee Health Science Center, Memphis, TN 38163
Surgery, College of Medicine, University of Tennessee Health Science Center, Memphis, TN 38163
1 To whom correspondence should be addressed. e-mail: jfain{at}utmem.edu
Haptoglobin is a putative adiposity marker because its concentration in blood is increased in obese humans. The present studies examined haptoglobin release by explants of adipose tissue in primary culture. Haptoglobin was released by explants of human visceral and subcutaneous adipose tissue at a nearly linear rate over 48 h. Explants of visceral adipose tissue released more haptoglobin than did explants of subcutaneous adipose tissue. The release of haptoglobin was quite variable, but there was a close correlation between haptoglobin release by visceral adipose tissue and that by explants of subcutaneous tissue from the same individual. Dexamethasone and niflumic acid, a cyclooxygenase-2 inhibitor, both inhibited haptoglobin release. There was release of haptoglobin by both isolated adipocytes and the adipose tissue matrix remaining after collagenase digestion of human adipose tissue.
However, the amount of haptoglobin released by human adipose tissue explants in primary culture was quite low in relationship to the circulating level of haptoglobin.
Supplementary key words dexamethasone interleukin-6 leptin interleukin-8 adiponectin interleukin-1ß niflumic acid lipopolysaccharide
![]()
CiteULike
Complore
Connotea
Del.icio.us
Digg
Reddit
Technorati What's this?
This article has been cited by other articles:
![]() |
Z. Berberoglu, A. Gursoy, N. Bayraktar, A. C. Yazici, N. Bascil Tutuncu, and N. Guvener Demirag Rosiglitazone Decreases Serum Bone-Specific Alkaline Phosphatase Activity in Postmenopausal Diabetic Women J. Clin. Endocrinol. Metab., September 1, 2007; 92(9): 3523 - 3530. [Abstract] [Full Text] [PDF] |
||||
![]() |
C. Chiellini, F. Santini, A. Marsili, P. Berti, A. Bertacca, C. Pelosini, G. Scartabelli, E. Pardini, J. Lopez-Soriano, R. Centoni, et al. Serum Haptoglobin: A Novel Marker of Adiposity in Humans J. Clin. Endocrinol. Metab., June 1, 2004; 89(6): 2678 - 2683. [Abstract] [Full Text] [PDF] |
||||
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
| All ASBMB Journals | Journal of Biological Chemistry |
| Molecular and Cellular Proteomics | ASBMB Today |